Timothy W Morris Selected Research

besifloxacin

5/2015	Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.
1/2015	Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.
12/2013	The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
5/2012	Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
5/2012	Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
1/2012	Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
1/2011	Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
1/2011	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
1/2011	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.
7/2010	Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Timothy W Morris Research Topics

Disease

13	Bacterial Conjunctivitis 05/2015 - 05/2009
4	Eye Infections 01/2016 - 08/2009
4	Infections 05/2012 - 07/2008
3	Bacterial Infections (Bacterial Infection) 01/2016 - 07/2008
1	Cataract (Cataracts) 01/2015
1	Conjunctivitis 11/2014
1	Dysgeusia (Parageusia) 12/2013
1	Pseudomonas Infections 01/2012

Drug/Important Bio-Agent (IBA)

14	besifloxacin FDA Link 05/2015 - 05/2009
10	SuspensionsIBA 05/2015 - 05/2009
5	FluoroquinolonesIBA 05/2012 - 08/2009
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2016 - 07/2008
4	Moxifloxacin (Avelox)FDA Link 05/2015 - 09/2009
4	Ophthalmic Solutions (Eye Drops)IBA 05/2015 - 09/2009
2	Capsules (Microcapsules)IBA 11/2014 - 12/2011
2	Virulence Factors (Pathogenicity Factors)IBA 11/2014 - 12/2011
2	RifamycinsIBA 07/2008 - 07/2008
1	VaccinesIBA 11/2014
1	Tetracycline (Achromycin)FDA LinkGeneric 12/2011
1	Erythromycin (Erycette)FDA LinkGeneric 12/2011
1	Trimethoprim (Proloprim)FDA LinkGeneric 12/2011
1	Azithromycin (Zithromax)FDA LinkGeneric 12/2011
1	MacrolidesIBA 10/2011
1	LactamsIBA 10/2011
1	Chloramphenicol (Chloromycetin)FDA Link 10/2011
1	Cephalosporins (Cephalosporin Antibiotics)IBA 10/2011
1	AminoglycosidesIBA 10/2011
1	GlycopeptidesIBA 10/2011
1	QuinolonesIBA 07/2008
1	CBR 2092IBA 07/2008